Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis

NCT07039110 · tracked via the Priya Life Science Germany tracker

Sponsor

AbbVie

Phase

Observational

Started

2025-09-09

Last updated

2026-09-09

Condition(s) studied

Plaque Psoriasis

Study summary

Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This study will assess the change in quality of life of risankizumab treatment in adult participants with moderate to severe plaque psoriasis real-world clinical practice.

Risankizumab is an approved drug for treating participants with Psoriasis. Approximately 700 participants who are prescribed risankizumab by their physician in accordance with local label will be enrolled in approximately 70 sites worldwide.

Participants will receive risankizumab as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 2.5 years.

There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Participants with a Confirmed diagnosis of moderate-to-severe plaque psoriasis with or without joint involvement according to the treating physician's clinical judgment, prior to time of enrollment. * Treatment with risankizumab is indicated per summary of product characteristics (SmPC) or local label and local prescribing/treatment guidelines. * Decision to treat with risankizumab is made prior to and independently of study participation. Exclusion Criteria: * History of a sleep disorder diagnosis which the patient is currently being treated for. * Current or recent (within the last 30 days) participation in an interventional clinical trial or an observational study. * Currently receiving other biologic treatments and/or small molecules including Janus kinase (JAK) inhibitors, tyrosine kinase 2 (TYK2) inhibitors, and phosphodiesterase 4 (PDE4) inhibitors for any reason.

Primary outcome measure(s)

Proportion of participants achieving a Dermatology Life Quality Index (DLQI) score of 0 or 1 — At 12 months
DLQI (Dermatology Life Quality Index) assesses symptoms and impacts of dermatologic diseases on quality of life. DLQI scores range from 0 (no at all) to 1 (a little).

Trial sites (83)

Facility	City	Region	Status
Dermatology Research Institute - Blackfoot Trail /ID# 276722	Calgary	Alberta	Recruiting
Rejuvenation Dermatology - Edmonton Downtown /ID# 276688	Edmonton	Alberta	Recruiting
Winnipeg Clinic /ID# 276751	Winnipeg	Manitoba	Recruiting
Wiseman Dermatology Research /ID# 276847	Winnipeg	Manitoba	Recruiting
Cca Medical Research /ID# 276944	Ajax	Ontario	Recruiting
Quinte dermatology /ID# 277497	Belleville	Ontario	Recruiting
Dermatrials Research /ID# 276714	Hamilton	Ontario	Completed
Lovegrove Dermatology /ID# 276797	London	Ontario	Recruiting
Lynderm Research Inc /ID# 276755	Markham	Ontario	Recruiting
Rejuvenation Dermatology Clinic Oakville /ID# 277492	Oakville	Ontario	Recruiting
JRB Research inc. /ID# 277730	Ottawa	Ontario	Recruiting
Factor Dermatology /ID# 278610	Ottawa	Ontario	Recruiting
SKiN Centre for Dermatology /ID# 277594	Peterborough	Ontario	Recruiting
Eternal Springtime Dermatology /ID# 278598	Thunder Bay	Ontario	Recruiting
North York Research /ID# 276835	Toronto	Ontario	Recruiting
Toronto Dermatology Centre /ID# 276846	Toronto	Ontario	Recruiting
Centre for Medical and Surgical Dermatology /ID# 278775	Whitby	Ontario	Recruiting
Dre Angelique Gagne-Henley M.D. inc. /ID# 276687	Saint-Jérôme	Quebec	Recruiting
Fakultni Nemocnice U Sv. Anny V Brne /ID# 275799	Brno	Brno-mesto	Recruiting
Fakultni nemocnice Bulovka /ID# 275540	Prague	Central Bohemia	Recruiting
Dermafit Centrum /ID# 275897	Pilsen	Plzeň Region	Recruiting
Dermamedest /ID# 275898	Prague	Praha 2	Recruiting
Nemocnice Ceske Budejovice /ID# 275541	České Budějovice	Czechia	Recruiting
Fakultni nemocnice Kralovske Vinohrady /ID# 275800	Prague	Czechia	Recruiting
Chu de Dijon /ID# 279900	Dijon	Bourgogne-Franche-Comté	Recruiting
Centre Hospitalier de Niort Georges Renon /ID# 279604	Niort	Deux-Sevres	Recruiting
Hopitaux Drome Nord - Romans /ID# 278109	Romans-sur-Isère	Drome	Recruiting
Dr. Rima Mohty /ID# 279951	Beauvais	Oise	Recruiting
Centre Hospitalier Du Mans /ID# 279899	Le Mans	Sarthe	Recruiting
Hopital d'Instruction des Armees Sainte-Anne /ID# 278106	Toulon	Var	Recruiting
Dr. med. Moritz Huber und Dr. med. Martin Heister /ID# 277627	Friedrichshafen	Baden-Wurttemberg	Recruiting
Dermakulm /Id# 277864	Kulmbach	Bavaria	Recruiting
Dermazent /Id# 280327	Munich	Bavaria	Recruiting
Hautaerzte am Nauener Tor /ID# 284579	Potsdam	Brandenburg	Recruiting
Klinikum Dortmund Klinikzentrum Mitte /ID# 284856	Dortmund	North Rhine-Westphalia	Recruiting
Universitaetsmedizin Mainz /ID# 278229	Mainz	Rhineland-Palatinate	Recruiting
Dermatologie Moelln Praxis Dr. Bodo Segert /ID# 277628	Mölln	Schleswig-Holstein	Recruiting
Universitaetsklinikum Hamburg-Eppendorf /ID# 277164	Hamburg	Germany	Recruiting
Cutaneum /ID# 277294	Hamburg	Germany	Recruiting
Private Practice - Dr. Mario Pawlak /ID# 277465	Heilbad Heiligenstadt	Germany	Recruiting

+ 43 more sites — see the full list on the official registry below.

More AbbVie trials in Germany

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia Active, not recruiting

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer Recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer Recruiting

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma Active, not recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer Recruiting

Other trials for the same condition

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) Active, not recruiting

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis Recruiting

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis Recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis Active, not recruiting

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07039110 on ClinicalTrials.gov ↗ ← All trials in Germany